Tags

Type your tag names separated by a space and hit enter

Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease.

Abstract

Quantitative biomarkers of oxidative damage, such as the F(2)-isoprostanes (IsoPs) and F(4)-neuroprostanes (F(4)-NeuroPs), may be useful in assessing progression and response to therapeutics in patients with Alzheimer's disease. F(2)-IsoPs and F(4)-NeuroPs are reproducibly increased in brain and cerebrospinal fluid of Alzheimer's disease patients; however, results in blood and urine have been conflicting. We tested the hypothesis that F(2)-IsoPs and F(4)-NeuroPs in plasma or urine quantitatively reflect oxidative damage to the central nervous system. Our results showed that urine levels of F(2)-IsoPs or their major metabolite were not significantly different between 56 Alzheimer's disease patients and 34 controls. In addition, urine and cerebrospinal fluid F(2)-IsoP levels in 32 Alzheimer's disease patients did not correlate. Supporting these conclusions, elevated rat cerebral F(2)-IsoPs and F(4)-NeuroPs after systemic exposure to kainic acid were not associated with a significant change in their plasma or urine levels. These results show that plasma and urine F(2)-IsoPs and F(4)-NeuroPs do not accurately reflect central nervous system levels of these biomarkers and are not reproducibly elevated in body fluids outside of central nervous system in Alzheimer's disease patients. These results should guide the organization of clinical trials now being planned for patients with Alzheimer's disease.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. tom.montine@mcmail.vanderbilt.edu

    , , , , , , , ,

    Source

    Annals of neurology 52:2 2002 Aug pg 175-9

    MeSH

    Aged
    Aged, 80 and over
    Alzheimer Disease
    Animals
    Biomarkers
    Brain
    F2-Isoprostanes
    Humans
    Kainic Acid
    Male
    Oxidation-Reduction
    Rats
    Rats, Sprague-Dawley
    Reference Values

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Research Support, U.S. Gov't, Non-P.H.S.
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    12210787

    Citation

    Montine, Thomas J., et al. "Peripheral F2-isoprostanes and F4-neuroprostanes Are Not Increased in Alzheimer's Disease." Annals of Neurology, vol. 52, no. 2, 2002, pp. 175-9.
    Montine TJ, Quinn JF, Milatovic D, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol. 2002;52(2):175-9.
    Montine, T. J., Quinn, J. F., Milatovic, D., Silbert, L. C., Dang, T., Sanchez, S., ... Morrow, J. D. (2002). Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Annals of Neurology, 52(2), pp. 175-9.
    Montine TJ, et al. Peripheral F2-isoprostanes and F4-neuroprostanes Are Not Increased in Alzheimer's Disease. Ann Neurol. 2002;52(2):175-9. PubMed PMID: 12210787.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. AU - Montine,Thomas J, AU - Quinn,Joseph F, AU - Milatovic,Dejan, AU - Silbert,Lisa C, AU - Dang,Theresa, AU - Sanchez,Stephanie, AU - Terry,Erin, AU - Roberts,L Jackson,2nd AU - Kaye,Jeffrey A, AU - Morrow,Jason D, PY - 2002/9/5/pubmed PY - 2002/9/19/medline PY - 2002/9/5/entrez SP - 175 EP - 9 JF - Annals of neurology JO - Ann. Neurol. VL - 52 IS - 2 N2 - Quantitative biomarkers of oxidative damage, such as the F(2)-isoprostanes (IsoPs) and F(4)-neuroprostanes (F(4)-NeuroPs), may be useful in assessing progression and response to therapeutics in patients with Alzheimer's disease. F(2)-IsoPs and F(4)-NeuroPs are reproducibly increased in brain and cerebrospinal fluid of Alzheimer's disease patients; however, results in blood and urine have been conflicting. We tested the hypothesis that F(2)-IsoPs and F(4)-NeuroPs in plasma or urine quantitatively reflect oxidative damage to the central nervous system. Our results showed that urine levels of F(2)-IsoPs or their major metabolite were not significantly different between 56 Alzheimer's disease patients and 34 controls. In addition, urine and cerebrospinal fluid F(2)-IsoP levels in 32 Alzheimer's disease patients did not correlate. Supporting these conclusions, elevated rat cerebral F(2)-IsoPs and F(4)-NeuroPs after systemic exposure to kainic acid were not associated with a significant change in their plasma or urine levels. These results show that plasma and urine F(2)-IsoPs and F(4)-NeuroPs do not accurately reflect central nervous system levels of these biomarkers and are not reproducibly elevated in body fluids outside of central nervous system in Alzheimer's disease patients. These results should guide the organization of clinical trials now being planned for patients with Alzheimer's disease. SN - 0364-5134 UR - https://www.unboundmedicine.com/medline/citation/12210787/Peripheral_F2_isoprostanes_and_F4_neuroprostanes_are_not_increased_in_Alzheimer's_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0364-5134&date=2002&volume=52&issue=2&spage=175 DB - PRIME DP - Unbound Medicine ER -